Regulatory Roundup: John Taylor to Serve as Acting Principal Deputy Commissioner after Joshua Sharfstein's Departure, and more. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: John Taylor to Serve as Acting Principal Deputy Commissioner after Joshua Sharfstein's Departure, and more.

ePT--the Electronic Newsletter of Pharmaceutical Technology

According to the FDA Press Office on Jan. 5, 2010, John Taylor, counselor to the commissioner, has been asked to serve as the acting principal deputy commissioner for the next 60 days. It was reported earlier this week that Joshua Sharfstein, principal deputy commissioner under Margaret Hamburg, was leaving the agency to work for the state of Maryland as secretary of health. Dr. Hamburg issued a memo on the subject today.

The US Pharmacopeia (USP) released proposals for universal standards to guide the content, language, format, and appearance of prescription drug labels. USP is seeking comments from pharmacists and other healthcare professionals for the newly proposed General Chapter <17> Prescription Container Labeling. Comments are due Mar. 31, 2011. The development of the proposed standards was led by the Institute of Medicine (IOM) and aim to “improve health literacy in the United States by bringing together government, industry, associations, and other groups to advance practical strategies that can be implemented to maximize patient comprehension of health information,” according to the USP notice. The core components of the standard proposals include labeling prescriptions in a patient-centered manner; emphasizing instructions and other important information; giving explicit instructions, including the purpose for use; improving readability; and limiting auxiliary information.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here